ABL Diagnostics presents three scientific posters at EMHH 2026

ABL Diagnostics unveiled three research posters at the European Meeting on HIV & Hepatitis in Barcelona, highlighting work in respiratory virus sequencing, HIV-1 genomic surveillance and ambient-stable qPCR for STI testing. The studies support the company’s push into NGS-based surveillance, decentralized testing and infectious disease data tools.

Why it matters: - ABL Diagnostics is using EMHH 2026 to showcase R&D that maps directly to higher-growth areas in infectious disease testing and genomic analysis. - The poster data support the company’s positioning in NGS-based surveillance, decentralized testing technologies and data-driven infectious disease management. - The work targets use cases where scalability, harmonized workflows and reduced cold-chain dependence can affect laboratory operations.

What happened: - ABL Diagnostics presented three scientific posters at the 24th European Meeting on HIV & Hepatitis, held June 10-12, 2026, in Barcelona, Spain. - The posters covered respiratory virus sequencing, HIV-1 genomic surveillance and ambient-stable qPCR for STI detection. - Dr. Sofiane Mohamed, head of research and development at ABL Diagnostics, said EMHH 2026 gives the company a chance to show progress in its R&D programs and their alignment with scientific and public health needs.

The details: - Poster 52 described a multiplexed NGS workflow for genomic analysis of Influenza A/B, RSV-A/B and SARS-CoV-2 using a unified approach. - ABL Diagnostics said the respiratory virus workflow could support large-scale surveillance frameworks and laboratory harmonization. - Poster 58 compared sequencing data from MGI DNBSEQ-E25 and Illumina MiSeq platforms. - The HIV-1 study showed concordance in detecting key genomic variants using standardized QCMD reference materials. - Poster 50 evaluated an ambient-stable, air-dryable qPCR enzyme formulation in multiplex STI detection workflows using the UltraGene Assay STD9 panel. - The STI study explored whether ambient-stable reagents could help molecular testing in decentralized and resource-limited laboratories. - The company linked each poster to a full PDF: Poster 52, Poster 58 and Poster 50.

Between the lines: - The posters point to a broader strategy built around platform flexibility rather than a single test format. - The respiratory sequencing and HIV surveillance work fits demand for scalable genomic monitoring tools. - The ambient-stable qPCR work speaks to a practical problem in diagnostics: how to keep testing functional where cold-chain logistics are difficult. - The release frames the results as analytical and investigational, not clinical performance claims.

What’s next: - ABL Diagnostics appears focused on advancing validation and market positioning for technologies tied to surveillance, decentralized testing and genomic interpretation. - The company says future development will remain aimed at laboratory workflows, scalability and data interpretation. - Any clinical use of the described products will depend on product-specific regulatory approvals.

The bottom line: - ABL Diagnostics is using EMHH 2026 to signal that its R&D pipeline is aimed at practical molecular tools for infectious disease surveillance and testing.